TCR-engineered T cell therapy
GPTKB entity
Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:cancer
immunotherapy |
| gptkbp:administeredBy |
infusion
|
| gptkbp:alternativeTo |
gene therapy
checkpoint inhibitor therapy |
| gptkbp:amendedBy |
gptkb:T_cells
|
| gptkbp:approvedBy |
clinical trials
|
| gptkbp:basedOn |
T cell receptor (TCR) engineering
|
| gptkbp:cause |
autoimmunity
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
Phase II Phase III |
| gptkbp:deliveredBy |
intravenous infusion
|
| gptkbp:developedBy |
early 2000s
biotechnology companies academic research institutions |
| https://www.w3.org/2000/01/rdf-schema#label |
TCR-engineered T cell therapy
|
| gptkbp:limitation |
HLA restriction
potential for cross-reactivity |
| gptkbp:mechanismOfAction |
genetic modification of T cells to express specific TCRs
|
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
| gptkbp:relatedTo |
personalized medicine
gene therapy adoptive cell transfer |
| gptkbp:requires |
genetic engineering
HLA matching ex vivo cell expansion lymphodepletion patient-specific or donor T cells vector delivery systems |
| gptkbp:sideEffect |
neurotoxicity
cytokine release syndrome off-target toxicity |
| gptkbp:studiedBy |
gptkb:National_Cancer_Institute
gptkb:rhabdomyosarcoma leukemia melanoma viral infections solid tumors academic hospitals |
| gptkbp:target |
intracellular antigens
mutated proteins tumor antigens viral antigens viral peptides |
| gptkbp:usedFor |
gptkb:cancer
infectious disease treatment |
| gptkbp:bfsParent |
gptkb:cell_surface_receptor
gptkb:TCR |
| gptkbp:bfsLayer |
6
|